Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease

AIMS: In the COMPASS trial, rivaroxaban 2.5 mg twice daily (bid) plus acetylsalicylic acid (ASA) 100 mg once daily (od) performed better than ASA 100 mg od alone in reducing the rate of cardiovascular disease, stroke, or myocardial infarction (MI) in patients with coronary artery disease (CAD) and p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Res
Main Authors: Cowie, Martin R, Lamy, André, Levy, Pierre, Mealing, Stuart, Millier, Aurélie, Mernagh, Paul, Cristeau, Olivier, Bowrin, Kevin, Briere, Jean-Baptiste
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Review Series from the Naples 2019 Joint Meeting of the ESC Working Groups on Myocardial Function and Cellular Biology of the Heart
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449563/
https://ncbi.nlm.nih.gov/pubmed/31807773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cvr/cvz278
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados